1. Scrip
  2. >>Business

Podcast: Afrigen Chief On mRNA Vaccine Candidate, IP Hoops, Market-Shaping Efforts

 
• By Anju Ghangurde

Petro Terblanche, managing director of Afrigen Biologics, talks to Scrip about a range of critical issues pertaining to the mRNA COVID-19 vaccine candidate being progressed under the wider WHO-backed technology hub initiative in South Africa and which is based on publicly-available Moderna data. Various tools and approaches are on hand to tackle the labyrinth of patents involved, though the hub, the executive underscores, will not infringe intellectual property rights.

Scrip Podcast Special

Afrigen Biologics has been in the spotlight after it developed an mRNA COVID-19 vaccine candidate based on publicly available Moderna, Inc. data. The Cape Town-based firm’s efforts are part of a wider World Health Organization-backed mRNA vaccine technology hub initiative in South Africa.

Afrigen’s managing director, Petro Terblanche, discusses with Scrip plans to progress the candidate, collaboration discussions with firms across countries including in the US and Canada, and production scale-up challenges

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip